Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress of lung transplantation. The use is detailed in a US-based study which highlights the clinical utility and operational benefits of the Technegas technology compared to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.…
Radiopharmaceutical medical imaging company Cyclopharm has received its first purchase orders from two United States Veterans Health Administration (VA) Hospitals – part of the largest integrated US Government health care system in the United States (US). The purchase orders for an initial five-year term apply to the installation and annual charges associated with the Technegas…
Radiopharmaceutical system manufacturer Cyclopharm has entered into an agreement to supply the Veterans Health Administration (VA), the largest US government health care system, with the pharmaceutical and consumable components of its Technegas imaging system. The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for…
AnteoTech engages with EV manufacturers to incorporate its anode materials Clean energy technology company AnteoTech is now engaged at different levels with the majority of European EV manufacturers as they seek to incorporate higher performing anodes in their vehicle batteries. At the recent The Battery Show, in Stuttgart, Germany the company continued to move towards…
Cyclopharm raises $20 million, seeks another $2 million Radiopharmaceutical imaging company Cyclopharm has successfully completed its institutional placement, raising $20 million before costs. The Placement attracted strong demand from both existing shareholders and from new institutional and sophisticated investors in Australia, Hong Kong, and the UK. A share purchase plan to raise up to $2.0…
Cyclopharm’s Technegas radiopharmaceutical imaging system has achieved a streamlined reimbursement approval process in the United States, boosting its prospects in what is the world’s largest market. The Sydney company has received a Coding Determination for Technegas from the Center for Medicare Medicaid Services (CMS), which means users will have a unique identifier which streamlines their…
Radiopharmaceutical manufacturer Cyclopharm has announced that Duke University Hospital in the United States has signed the first commercial contract for the use of its Technegas lung imaging system in the United States. Following the approval of Technegas by the United States Food and Drug Administration (USFDA) in September, this agreement signifies a major milestone for…
The US Food and Drug Administration has approved Cyclopharm’s lung imagining technology Technegas, opening up a US$180 million market that has the potential to quadruple the size of Cyclopharm’s existing Pulmonary Embolism (PE) market. Technegas is an ultra-fine dispersion of the radiopharmaceutical Technetium-99m within a gas used in diagnostic functional lung imaging in 64 countries…
